Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down - What's Next?

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $39.75, but opened at $32.72. Supernus Pharmaceuticals shares last traded at $34.98, with a volume of 255,949 shares traded.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $57.00 to $36.00 in a report on Wednesday.

Supernus Pharmaceuticals Price Performance

The stock's 50 day simple moving average is $37.55 and its two-hundred day simple moving average is $35.27. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the business's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.30% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Pacer Advisors Inc. increased its stake in shares of Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company's stock valued at $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Woodline Partners LP increased its stake in shares of Supernus Pharmaceuticals by 124.8% in the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after acquiring an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Supernus Pharmaceuticals by 248.0% in the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock valued at $10,581,000 after acquiring an additional 208,552 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $6,847,000. Finally, Great Lakes Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $6,131,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.